Education
About Us
Working with TipRanks
Follow Us
Nuvalent (NUVL)
NASDAQ:NUVL
NUVL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$55.54 - $106.32
Previous CloseN/A
Volume65.93K
Average Volume (3M)398.19K
Market Cap
$5.74B
Enterprise Value$4.48B
Total Cash (Recent Filing)$1.01B
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Nov 06, 2025EPS Estimate
-1.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.39
Shares Outstanding66,669,586
10 Day Avg. Volume396,815
30 Day Avg. Volume398,191
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.78
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-12.36
Forecast
1Y Price Target
$116.00Price Target Upside49.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
Bulls Say, Bears Say
Bulls Say
Financial StabilityThe company reported cash and cash equivalents of $1.0 billion, which is expected to provide a cash runway into 2028.
Market PotentialThe upcoming ROS1 and TKI pre-treated ALK commercial launches are anticipated to have significant sales potential.
Regulatory MilestonesThe completion of the rolling NDA submission for zidesamib in TKI pretreated ROS1+ NSCLC patients is a key execution milestone for Nuvalent, setting the stage for first approval and commercial launch.
Bears Say
Financial PerformanceThe company reported no revenue for the quarter, in line with consensus, and a net loss of $1.39 per share, compared to the consensus estimated net loss of $1.22 per share.
Market SkepticismShort interest in Nuvalent is relatively high at 13.3% of the float, indicating some market skepticism or potential for stock volatility.
Nuvalent News
NUVL FAQ
What was Nuvalent’s price range in the past 12 months?
Nuvalent lowest stock price was $55.53 and its highest was $106.32 in the past 12 months.
What is Nuvalent’s market cap?
Nuvalent’s market cap is $5.74B.
When is Nuvalent’s upcoming earnings report date?
Nuvalent’s upcoming earnings report date is Nov 06, 2025 which is in 40 days.
How were Nuvalent’s earnings last quarter?
Nuvalent released its earnings results on Aug 07, 2025. The company reported -$1.39 earnings per share for the quarter, missing the consensus estimate of -$1.225 by -$0.165.
Is Nuvalent overvalued?
According to Wall Street analysts Nuvalent’s price is currently Undervalued.
Does Nuvalent pay dividends?
Nuvalent does not currently pay dividends.
What is Nuvalent’s EPS estimate?
Nuvalent’s EPS estimate is -1.36.
How many shares outstanding does Nuvalent have?
Nuvalent has 66,669,586 shares outstanding.
What happened to Nuvalent’s price movement after its last earnings report?
Nuvalent reported an EPS of -$1.39 in its last earnings report, missing expectations of -$1.225. Following the earnings report the stock price went down -6.565%.
Which hedge fund is a major shareholder of Nuvalent?
Currently, no hedge funds are holding shares in NUVL
Nuvalent Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$116.00 (49.64% Upside)
$116.00 (49.64% Upside)
Blogger Sentiment
Bullish
NUVL Sentiment 100%
Sector Average 73%
Sector Average 73%
Hedge Fund Trend
Decreased
By 737.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 3.4%
Last 30 Days ▲ 2.5%
Last 30 Days ▲ 2.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-22.82%
12-Months-Change
Fundamentals
Return on Equity
-43.55%
Trailing 12-Months
Asset Growth
54.10%
Trailing 12-Months
Company Description
Nuvalent
Nuvalent, Inc. is an innovative biotechnology company focused on creating small molecule medicines for patients with cancer. The company specializes in developing precision-targeted therapies for clinically proven kinase targets in cancer treatment. Nuvalent's core products are designed to address the limitations of existing therapies, with a focus on resistance, selectivity, and brain penetration to provide significant improvements for patients.
NUVL Stock 12 Month Forecast
Average Price Target
$116.00
▲(49.64% Upside)
Technical Analysis
Ownership Overview
32.64% Insiders
22.93% Mutual Funds
<0.01% Other Institutional Investors
33.07% Public Companies and
Individual Investors